share_log

Ardelyx | 8-K: Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update

Ardelyx | 8-K: Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update

Ardelyx | 8-K:Ardelyx 公布2024年第一季度财务业绩并提供业务最新情况
美股sec公告 ·  05/02 16:10
Moomoo AI 已提取核心信息
On May 2, 2024, Ardelyx, Inc., a biopharmaceutical company, reported its financial results for the first quarter ending March 31, 2024. The company announced substantial revenue growth, driven by its two main products, IBSRELA and XPHOZAH. Ardelyx recorded $45.6 million in product-related revenue for the quarter, with $28.4 million from IBSRELA and $15.2 million from XPHOZAH. The company ended the quarter with approximately $203 million in cash and investments. The financial report highlighted significant year-over-year growth and the successful commercial performance of both products. Ardelyx expects full-year 2024 U.S. net product sales revenue for IBSRELA to be between $140.0 and $150.0 million. The company also announced the appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy. Total revenue for the quarter was $46.0 million...Show More
On May 2, 2024, Ardelyx, Inc., a biopharmaceutical company, reported its financial results for the first quarter ending March 31, 2024. The company announced substantial revenue growth, driven by its two main products, IBSRELA and XPHOZAH. Ardelyx recorded $45.6 million in product-related revenue for the quarter, with $28.4 million from IBSRELA and $15.2 million from XPHOZAH. The company ended the quarter with approximately $203 million in cash and investments. The financial report highlighted significant year-over-year growth and the successful commercial performance of both products. Ardelyx expects full-year 2024 U.S. net product sales revenue for IBSRELA to be between $140.0 and $150.0 million. The company also announced the appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy. Total revenue for the quarter was $46.0 million, compared to $11.4 million in the same period of 2023. Research and development expenses were $10.6 million, and selling, general and administrative expenses were $53.0 million. The net loss for the quarter was $26.5 million, or $(0.11) per share. The company also provided important safety information for IBSRELA and XPHOZAH, highlighting the risk of serious dehydration in pediatric patients and contraindications in certain individuals.
2024年5月2日,生物制药公司Ardelyx, Inc. 公布了截至2024年3月31日的第一季度财务业绩。该公司宣布收入大幅增长,这得益于其两大主要产品IBSRELA和XPHOZAH。Ardelyx在本季度创下了4560万美元的产品相关收入,其中2,840万美元来自IBSRELA,1,520万美元来自XPHOZAH。该公司在本季度末拥有约2.03亿美元的现金和投资。财务报告强调了这两种产品的显著同比增长以及成功的商业表现。Ardelyx预计,IBSRELA2024年全年美国的净产品销售收入将在1.4亿美元至1.50亿美元之间。该公司还宣布任命迈克·凯利赫为企业发展和战略执行副总裁。该季度的...展开全部
2024年5月2日,生物制药公司Ardelyx, Inc. 公布了截至2024年3月31日的第一季度财务业绩。该公司宣布收入大幅增长,这得益于其两大主要产品IBSRELA和XPHOZAH。Ardelyx在本季度创下了4560万美元的产品相关收入,其中2,840万美元来自IBSRELA,1,520万美元来自XPHOZAH。该公司在本季度末拥有约2.03亿美元的现金和投资。财务报告强调了这两种产品的显著同比增长以及成功的商业表现。Ardelyx预计,IBSRELA2024年全年美国的净产品销售收入将在1.4亿美元至1.50亿美元之间。该公司还宣布任命迈克·凯利赫为企业发展和战略执行副总裁。该季度的总收入为4,600万美元,而2023年同期为1140万美元。研发费用为1,060万美元,销售、一般和管理费用为5,300万美元。该季度的净亏损为2650万美元,合每股亏损0.11美元。该公司还为IBSRELA和XPHOZAH提供了重要的安全信息,重点介绍了儿科患者严重脱水的风险和某些人的禁忌症。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息